|
Article ID: 700447 Scripps Research InstituteTwo new studies by scientists at Scripps Research are bringing Ebola virus’s weaknesses into the spotlight, showing for the first time exactly how human and mouse antibodies can bind to the virus and stop infection—not only for Ebola virus, but for other closely related pathogens as well. Released:12-Sep-2018 4:45 PM EDT |
|
Article ID: 699544 Northern Arizona UniversityGeneticist Jason Ladner talks about the study, which underscores the need for focused prevention efforts among survivors and better capacity to detect new cases of the deadly virus. Released:24-Aug-2018 6:05 PM EDTChannels: All Journal News, Infectious Diseases, Ebola Ebola, Genetics, The Lancet Infectious Diseaes, Centers for Disease Control and Prevention (CDC), World Health Organisation, U.S. Army Medical Research Institute of Infectious Diseases, National Institiutes Of Health, International Rescue Committee, West Africa |
|
Article ID: 698671 Texas Biomedical Research InstituteA new study at Texas Biomedical Research Institute is shedding light on the role of specific proteins that trigger a mechanism allowing Ebola virus to enter cells to establish replication. Released:8-Aug-2018 10:00 AM EDT |
Article ID: 698593 Ohio State UniversityA uniquely designed experimental vaccine against Zika virus has proven powerful in mice, new research has found. Released:6-Aug-2018 10:05 AM EDT |
|
Article ID: 698417 Georgetown University Medical CenterWASHINGTON — Georgetown University professors offer expertise for journalists seeking interviews in a variety of subjects related to Ebola. Topics include infectious disease control and treatment, vaccine development, clinical trials, global health security, and international health regulations. To schedule an interview, please contact Karen Teber at km463@georgetown. Released:1-Aug-2018 2:05 PM EDTChannels: Infectious Diseases, Vaccines, Ebola, Influenza, Public Health, Local - DC, Local - DC Metro |
|
Article ID: 698263 Vanderbilt University Medical CenterResearchers at Vanderbilt University Medical Center and their colleagues are a step closer to developing a broadly effective antibody treatment against the three major Ebola viruses that cause lethal disease in humans. Released:30-Jul-2018 3:15 PM EDT |
Article ID: 697772 Scripps Research InstituteNew Scripps Research study offers guidance for more effective Ebola vaccines Released:23-Jul-2018 3:05 PM EDT |
|
Article ID: 696615 Perelman School of Medicine at the University of PennsylvaniaProtein fragments, called amyloid fibrils, in human semen significantly increase Ebola virus infection and protect the virus against harsh environmental conditions such as heat and dehydration. Follow-up studies from the 2014 epidemic found that men can harbor the virus in their semen for at least 2.5 years, with the potential to transmit the virus sexually during that time. Targeting amyloids in semen may prevent a sexually transmitted spread of the Ebola virus. Released:25-Jun-2018 3:50 PM EDT |
Released:21-May-2018 7:05 PM EDT |